Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Research & Development (2016 - 2025)

Historic Research & Development for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to $216.2 million.

  • Ultragenyx Pharmaceutical's Research & Development rose 2710.2% to $216.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $734.5 million, marking a year-over-year increase of 951.75%. This contributed to the annual value of $697.9 million for FY2024, which is 762.06% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Research & Development is $216.2 million, which was up 2710.2% from $164.7 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Research & Development registered a high of $237.3 million during Q3 2022, and its lowest value of $113.2 million during Q2 2021.
  • Moreover, its 5-year median value for Research & Development was $164.7 million (2025), whereas its average is $162.9 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Research & Development surged by 10922.52% in 2022 and then plummeted by 3373.49% in 2023.
  • Quarter analysis of 5 years shows Ultragenyx Pharmaceutical's Research & Development stood at $123.0 million in 2021, then surged by 38.85% to $170.8 million in 2022, then decreased by 6.0% to $160.6 million in 2023, then rose by 16.95% to $187.8 million in 2024, then increased by 15.15% to $216.2 million in 2025.
  • Its last three reported values are $216.2 million in Q3 2025, $164.7 million for Q2 2025, and $165.8 million during Q1 2025.